Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a substituted benzimidazole proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. It is available in oral (delayed-release tablets, granules for oral suspension) and intravenous formulations.
## Primary Indications
* Short-term treatment of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Prophylaxis of stress-induced upper gastrointestinal bleeding (IV, off-label/hospital protocol dependent).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose 40 mg twice daily. Doses up to 240 mg daily have been used; individualize based on clinical response.
* **Stress Ulcer Prophylaxis (Off-label):** Generally 40 mg IV once daily or every 12 hours based on institutional protocol.
## Pediatric Dosing
* **GERD/Erosive Esophagitis (5 years and older):**
* 15 kg to <40 kg: 20 mg once daily.
* 40 kg or greater: 40 mg once daily.
* **Safety/Efficacy:** Not established for patients under 5 years of age.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** No specific adjustment required, but use with caution in severe liver disease. Monitor for elevated liver enzymes.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, constipation, flatulence.
* **Serious:** Acute interstitial nephritis, *Clostridioides difficile*-associated diarrhea, vitamin B12 deficiency (long-term use), hypomagnesemia, bone fractures (hip, wrist, spine), and cutaneous/systemic lupus erythematosus.
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of drugs like atazanavir, nelfinavir, ketoconazole, and iron salts.
* **Methotrexate:** May increase serum levels of methotrexate, particularly in high-dose therapy.
* **Warfarin:** Monitor INR/PT (potential for increased anticoagulant effect reported with some PPIs).
## Monitoring
* **Short-term:** Resolution of GERD symptoms.
* **Long-term:** Monitor magnesium levels if therapy exceeds 1 year, and assess for signs of B12 deficiency and hypomagnesemia. Assess for symptoms of *C. difficile* (persistent watery diarrhea).
## Clinical Pearls
* **Administration:** Tablets should be swallowed whole; do not crush or chew. Granules can be administered via nasogastric tube (verify tube size/clog risk).
* **Timing:** For best efficacy, administer tablets 30–60 minutes before a meal (typically breakfast).
* **Deprescribing:** Long-term PPI use should be periodically re-evaluated due to risks of enteric infections, fractures, and nutrient malabsorption.
* **IV to Oral:** Transition to oral therapy as soon as patient is stable and able to tolerate oral intake.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice protocols vary by institution. Always verify dosages, contraindications, and drug interactions against current, peer-reviewed clinical databases or official FDA-approved prescribing information (package insert) before prescribing or administering medication.
